Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Perioral dermatitis

Also known as: peri-oral dermatitis, periorificial dermatitis, periorifacial dermatitis, periocular dermatitis

Perioral dermatitis is an inflammatory facial rash made up of small bumps, often with dryness or irritation, around the mouth. Similar eruptions can affect the nose or eyes. Recognising its pattern helps a clinician choose appropriate care and review possible triggers.

In plain English — This rash usually forms small bumps around the mouth, and sometimes around the nose or eyes. A clinician can identify the pattern, review skincare and medicines, and arrange treatment to help it settle. A simple, well-tolerated skincare routine can support that care.

Evidence status

Limited

Dermatology references describe a recognisable facial eruption and established clinical approaches to care. A systematic review searching to February 2021 judged important treatment outcomes low or very low certainty; a small 2026 paediatric trial adds evidence without settling the preferred treatment. Diagnosis, medicine selection and changes to prescribed steroids require clinical assessment.

What perioral dermatitis is and how it presents#

Perioral dermatitis is a facial inflammatory eruption with clusters of small papules, sometimes pustules, and variable dryness, scale, burning or soreness. Periorificial dermatitis is the broader term when the eruption surrounds the nose or eyes as well as, or instead of, the mouth. A narrow strip beside the lip may remain clear.[1, 2, 3]

Younger adult women are commonly affected, but childhood cases are well documented. In richly pigmented skin, changes in texture and darker or purplish bumps may be more noticeable than redness. This makes distribution and symptoms important alongside colour.[1, 5]

The useful distinction is the whole pattern. Comedones support consideration of acne; flushing and visible facial vessels suggest assessment for rosacea; scalp or brow scale points towards seborrhoeic dermatitis. These conditions can complicate the same consultation. An isolated feature is not a diagnosis.[2, 3]i

Use of perioral dermatitis in aesthetic practice#

For a skincare professional, the value of recognising this pattern is a better consultation and referral. Useful records include where the rash began, symptoms, products introduced, previous treatment and all routes of steroid exposure, including inhalers or nasal sprays. A client may not think of a prescribed medicine as relevant to their facial skincare.[1, 3]

Clinical care often simplifies unnecessary facial products and provides a medical treatment where appropriate. Supportive skincare fits around that plan. The separate impaired skin barrier entry covers irritation and barrier support; it does not replace the diagnostic assessment of this particular eruption.[1, 2, 3]

Contraindications and cautions#

An active, unexplained rash is a reason to defer elective exfoliation or other potentially irritating work on the affected area while its cause is assessed. The precaution reflects the skin’s sensitivity and possible product involvement; timing depends on clinical assessment.[1, 2, 3]i

Suspected POD in someone using facial topical steroids needs a clinician-led review of that prescription. Necessary inhaled, nasal or oral steroids for another illness must remain under the responsible prescriber’s direction. A skincare consultation must not become an unsupervised withdrawal plan.[2, 3]i

Pregnancy, childhood, concurrent illness, allergies and medicine history affect treatment choice. An adult’s previous prescription is not transferable to a child or to pregnancy; guidance provides different medical options for those circumstances.[2, 3]

Clinical uses and the evidence behind them#

Established clinical approaches

UK dermatology guidance describes topical medicines for selected milder presentations and oral antibiotics, including tetracyclines, for other patients. Exposure review and tolerability are part of that care. These are medical choices, rather than an aesthetic treatment menu.[1, 3]

Comparative treatment evidence

Gray and colleagues’ systematic review included 11 studies and 733 children and adults, with searches ending on 2 February 2021.[4] Oral tetracycline may improve clinician-rated severity from day 20; certainty was low.[4]For pimecrolimus, the four-week severity estimate was a mean difference of −0.49 (95% CI −1.02 to 0.04; 164 participants; low certainty). That interval includes no difference. The review declared no funding, while one author disclosed financial relationships with Galderma and Meda Pharma.[4]

More recent paediatric research

A Pfizer-funded 2026 pilot randomised 23 children with facial POD, mean age 3.5 years, to crisaborole 2% ointment or vehicle. Four treatment weeks were followed by four observation weeks. Both groups improved; between-group efficacy differences were not statistically significant. The small study and missing follow-up limit precision. It is useful preliminary evidence, not an established replacement for routine care.[6]

Selecting care for perioral dermatitis#

Selection starts with the diagnosis and the person’s circumstances: distribution, symptom burden, persistence, previous exposure, age and tolerance. A clinical review can distinguish an inflammatory periorificial eruption from contact dermatitis, acne or another facial condition. If the pattern is uncertain, targeted tests may be appropriate.[1, 3][2]

For supportive care, the important property is tolerance within the agreed plan. A bland, light formulation may suit some patients; a heavy occlusive product may aggravate others. The term “barrier repair” alone does not identify the right finished product. Sunscreen form and tolerability can be discussed without abandoning photoprotection.[1, 2, 3]

Adverse effects and their management#

The rash itself can burn, feel tight or become distressing. Treatment can add unwanted effects: the systematic review reported abdominal discomfort with oral tetracycline and local irritation with topical treatments. Burning or stinging also occurred in the 2026 crisaborole pilot. New symptoms therefore need to be considered against both the condition and the actual medicine used.[4, 6]

Product names, timing and the change in symptoms help the treating clinician assess a suspected reaction. Continuing to add actives to an increasingly sore eruption makes that assessment harder; the supportive aim is a tolerable routine and a clear account of what happened.[1, 3]

Referral and scope boundaries#

A persistent, recurrent or diagnostically uncertain perioral eruption belongs with a GP or suitably qualified clinician. Important handover details are the rash’s distribution, duration, symptoms, steroid exposure and response to previous treatment. Dermatology assessment may be needed for atypical or treatment-resistant disease. Swabs or scrapings can investigate infection, patch testing can assess suspected contact allergy, and biopsy can clarify an uncertain diagnosis.[1, 2, 3]i[2]

Periocular skin involvement needs particular care. Eye pain, changed vision or a very red eye warrants urgent assessment through an urgent GP service or NHS 111; these are possible signs of an eye problem, not findings to relabel as ordinary facial irritation.[8]i

The practitioner contribution is recognition, documentation, supportive care within competence and timely referral. Diagnosis and prescription changes remain with the responsible clinician.[1, 2, 3]i

Mechanism of action#

This is a condition, so the relevant mechanism is its pathogenesis. Barrier disturbance and inflammatory responses to exposures are proposed contributors, but a single established cause does not explain all cases. The role of organisms cultured from lesions remains uncertain. A clinical treatment response alone does not resolve that causal question.[2]

Commonly misstated claims#

Steroid withdrawal and recurrence

Claim heard:“If the rash returns without the steroid, the skin must need it.”

Literature finding: Clinical guidance recognises a temporary flare after withdrawal of a facial topical steroid. A sequence of suppression and recurrence can therefore be misleading: it does not by itself demonstrate that the original treatment was appropriate for the eruption.[2, 3]i

Supported statement: Short-term suppression and subsequent flare must be interpreted in the context of the diagnosis.

Previous steroid exposure

Claim heard:“Everyone with perioral dermatitis has used a steroid.”

Literature finding: In a US retrospective clinic series, 58.1% of 222 children, mean age 6.6 years, had a recorded history of steroid use before POD began. The records covered June 2002 to March 2014; funding was not reported in the available abstract. This is a paediatric exposure association, not a causal fraction or an estimate for all adult patients.[5]

Supported statement: Steroid exposure is an important clinical association, not a universal requirement for the diagnosis.

Toothpaste allergy and diagnosis

Claim heard:“Toothpaste allergy reports prove fluoride causes perioral dermatitis.”

Literature finding: A 2020 report described two adults with contact cheilitis and evidence of tin allergy associated with toothpaste. Both tested negatively to sodium fluoride. The authors declared no conflicts. This was an investigation of contact allergy, not a controlled POD study.[7]i

Supported statement: The diagnosis and the specific substance identified in an allergy report must travel with its conclusion.

Areas of remaining uncertainty#

  • Comparative treatment and relapse evidence remains limited, particularly for children; clinical review and response assessment matter more than a promised universal course.[4][6]
  • The part played by each exposure varies between patients; an exposure history supports assessment but cannot assign blame by itself.[2][5]

Frequently asked questions#

Can it affect the area around the eyes?

Yes. Periorificial dermatitis includes periocular and perinasal patterns as well as the more familiar perioral distribution.[1, 2, 3]

What information is useful at a medical appointment?

The rash’s onset and distribution, symptoms, skincare products, medicines and what changed after previous treatment are useful. This includes steroid creams used elsewhere and inhaled or nasal medicines.[1, 3]

How long does it take to settle?

Clinical references describe improvement over weeks, but the course varies and recurrence is possible. Follow-up is more useful than promising an exact clearance date.[1, 2, 3]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. British Association of Dermatologists. Peri-oral dermatitis. Patient information leaflet. Updated February 2023.Tier 4Supports: Complete public HTML personally retrieved 16 September 2026. Definition, appearance across skin tones, clinical diagnosis, medical care and supportive skincare. The leaflet explicitly describes itself as a consensus of BAD representatives. Its nearly-always steroid-exposure wording is not generalised to children; the primary paediatric cohort is retained separately. The listed February 2026 review date has passed; no newer review is invented.Funding / interest: BAD institutional patient information, reviewed by its Patient Information Lay Review Panel. No article-specific manufacturer funding declaration located.
  2. Shah N. Periorificial dermatitis. DermNet. July 2022.Tier 4Supports: Complete clinical text retrieved. Perioral/perinasal/periocular terminology, relative vermilion sparing, differential, investigations, possible mechanisms and clinical cautions. Necessary inhaled/nasal/oral corticosteroids are distinguished from inappropriate facial topical use. Narrative reference, not a diagnostic-accuracy or causal study.Funding / interest: DermNet reference; no article-specific sponsor or author conflict declaration located. The site displays advertising.
  3. Primary Care Dermatology Society. Perioral dermatitis / periocular dermatitis. Clinical guidance. Updated 17 December 2023.Tier 4Supports: Full clinical content retrieved. Morphology, steroid/product exposure history, recognised withdrawal flare, topical and systemic medical options, recurrent symptoms. Prescribing and tapering instructions are not reproduced. Lead author listed as Dr Tim Cunliffe.Funding / interest: PCDS names pharmaceutical website sponsors and states they have had no involvement in website content or conference programmes. No article-specific funding declaration located.
  4. Gray NA, Tod B, Rohwer A, Fincham L, Visser WI, McCaul M. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(3):380–390. doi:10.1111/jdv.17817. PMID:34779023.Tier 1Supports: Publisher abstract, declarations and references plus MEDLINE abstract via Europe PMC personally retrieved. Search 2 February 2021; 11 studies, 733 participants; GRADE assessment. Oral tetracycline and pimecrolimus results, pooled pimecrolimus estimate and adverse effects retained within abstract scope. Full individual-study tables not retrieved; no reconstructed subgroup or regimen claim.Funding / interest: Review funding: none declared. W.I. Visser disclosed speaker/consultancy fees and travel, accommodation, subsistence and conference-registration payments from Galderma and Meda Pharma. Other review authors declared no conflicts. This is a review-level disclosure, not proof that the included trials were independent.
  5. Goel NS, Burkhart CN, Morrell DS. Pediatric periorificial dermatitis: clinical course and treatment outcomes in 222 patients. Pediatr Dermatol. 2015;32(3):333–336. doi:10.1111/pde.12534. PMID:25847356.Tier 3Supports: Primary MEDLINE abstract personally retrieved through Europe PMC. Retrospective University of North Carolina clinic records, June 2002–March 2014; 222 children, mean age 6.6 years, facial eruption. Prior steroid use reported in 58.1%; 59% had clinic follow-up at mean 3.8 months, and 71.8% of those with documented follow-up had complete resolution. Follow-up denominator and combined treatments prevent a whole-cohort treatment-success claim. Full text not retrieved.Funding / interest: Funding and conflicts not stated in retrieved abstract; neither independence nor commercial sponsorship is established.
  6. Ollech A, Aluma BB, Weiss-Fink A, Horev A, Toker O, Czarnowicki T. Crisaborole 2% for Pediatric Periorificial Dermatitis: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study. Ann Dermatol. 2026;38(3):177–182. doi:10.5021/ad.25.227. PMID:42244271.Tier 2Supports: Complete primary XML personally retrieved via Europe PMC. Single-centre paediatric pilot, 23 participants, mean age 3.5 years, facial POD; four treatment weeks and four observation weeks. Both arms improved; no statistically significant between-group efficacy difference. Burning/stinging and missing follow-up matter. Internal inconsistencies in arm percentages/completion counts are logged in research; those figures are not reproduced.Funding / interest: Pfizer Inc. supported the work, grant 57944115. Authors declared nothing to disclose. Manufacturer funding is retained in the prose.
  7. van Amerongen CCA, de Groot A, Volkering RJ, Schuttelaar MLA. Cheilitis caused by contact allergy to toothpaste containing stannous (tin) — two cases. Contact Dermatitis. 2020;83(2):126–129. doi:10.1111/cod.13532. PMID:32212164.Tier 3Supports: Full primary HTML and patch-test table retrieved. Two adults aged 69 and 62 with contact cheilitis/oral-perioral symptoms had reactions supporting tin contact allergy; sodium fluoride tests were negative. These are different diagnoses from a controlled study of periorificial dermatitis and do not establish a fluoride-wide trigger.Funding / interest: Authors declared no conflicts of interest. No separate funding statement located in retrieved full text. Product identification in the report is not treated as a present-day brand/formula verdict.
  8. NHS. Blepharitis. Reviewed 12 June 2025.Tier 4Supports: Official patient guidance directly retrieved. Eye pain, vision change or very red eyes require urgent GP/111 assessment. Used as an ocular safety boundary, not evidence that POD itself causes each red flag.Funding / interest: NHS institutional patient guidance; not a manufacturer efficacy source.